scholarly journals IL‐23/IL‐17 axis and soluble receptors isoforms sIL‐23R and sIL‐17RA in patients with rheumatoid arthritis‐presenting periodontitis

2021 ◽  
Author(s):  
Ruth Rodríguez‐Montaño ◽  
Ana Guilaisne Bernard‐Medina ◽  
Edith Oregon‐Romero ◽  
Vianeth María del Carmen Martínez‐Rodríguez ◽  
María Luisa Pita‐López ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Soluble Receptors

The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis

2010 ◽  
Vol 32 (1) ◽  
pp. 199-206 ◽  
Author(s):  
Peter Oelzner ◽  
Sybille Franke ◽  
Gabriele Lehmann ◽  
Thorsten Eidner ◽  
Gert Hein ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Postmenopausal Women ◽  
Soluble Receptors

scholarly journals Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF-αand Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Martin Schulz ◽  
Helmut Dotzlaw ◽  
Gunther Neeck
Keyword(s):  
Rheumatoid Arthritis ◽  
Ankylosing Spondylitis ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Serum Levels ◽  
Tnf Receptor ◽  
Healthy Individuals ◽  
Inflammation Markers ◽  
Soluble Receptors ◽  
Patient Groups

The effects of the TNF-αblockers infliximab or etanercept on the levels of TNF-α, TNF-receptor 1 (TNF-R1), and TNF-receptor 2 (TNF-R2), as well as the levels of the inflammation markers CRP and IL-6, were measured in ankylosing spondylitis (AS) and rheumatoid arthritis (RA) patients receiving treatment with either compound. We found that RA patients tend to have higher levels of TNF-αthan both healthy individuals and AS patients prior to treatment (P<0.05). We measured greatly increased levels of TNF-αin both the AS and RA etanercept patient groups during the course of treatment, while in the infliximab treated patients, the amount of TNF-αmeasured remained unchanged. Elevated TNF-αin the etanercept treated patients does not appear to be a significant risk factor for the spontaneous development of further autoimmune diseases in our study group. Increased levels of TNF-R1 were determined in both AS (P<0.05) and RA (P<0.001) patients when compared to healthy controls. In AS patients, the levels of TNF-R1 dropped significantly when treated with either infliximab (P<0.01) or etanercept (P<0.001). In contrast, the levels of this receptor remained unchanged in RA patients treated with either compound.

Similar Serum Levels of IL-6 and its Soluble Receptors in Patients with HCV-Related Arthritis and Rheumatoid Arthritis: A Pilot Study

2012 ◽  
Vol 25 (1) ◽  
pp. 281-285 ◽  
Author(s):  
A. Riccio ◽  
L. Postiglione ◽  
P. Sabatini ◽  
M. Linvelli ◽  
I. Soriente ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Pilot Study ◽  
Healthy Subjects ◽  
Serum Levels ◽  
High Serum ◽  
Control Group ◽  
Serum Concentrations ◽  
Soluble Receptors ◽  
Significant Difference

The high serum levels of Interleukin-6 (IL-6) and its soluble receptors (sIL-6r and sgp 130), described in the course of Rheumatoid Arthritis (RA), have been linked to the enhanced activity of this cytokine in this disorder. In this study, the serum concentrations of IL-6 and its soluble receptors were determined in a group of patients with HCV-related arthritis (HCVrA), a condition resembling RA in several aspects, and then compared to those found in a sample of subjects affected by RA. Twenty-one patients with HCVrA, 24 patients with RA and 20 healthy subjects (control group) were examined. Different ELISA methods were used for determination of serum concentrations of IL-6, sIL-6r and sgp 130. Increased IL-6 serum levels were found in 15 (71%) of the patients with HCVrA and in 16 (62%) of those with RA. Eight (38%) of the patients with HCVrA and 11 (46%) of those with RA denoted high levels of sIL-6r, while sgp 130 levels were elevated in 21 (76%) of the patients with HCVrA and in 16 (69%) of those with RA. A significant difference between the median values of sIL-6r and sgp 130 levels in the two groups of patients versus controls was found. A mild correlation of these parameters with RF levels was detected in the RA group. Furthermore, in HCVrA patients the serum levels of IL-6, sIL-6r and sgpl30 appeared unrelated to HCV viraemia and to levels of transaminases. The enhanced serum levels of IL-6 in HCVra patients indicate an increased synthesis and hyperactivity of this cytokine in HCVrA, and the substantial similarity of the behaviour of IL-6 and its serum receptors in the two groups of patients suggests common mechanisms with RA, in which the function of IL-6 is central.

CIRCULATING CONCENTRATIONS AND PRODUCTION OF CYTOKINES AND SOLUBLE RECEPTORS IN RHEUMATOID ARTHRITIS PATIENTS: EFFECTS OF A SINGLE DOSE METHOTREXATE

Rheumatology ◽  
1994 ◽  
Vol 33 (11) ◽  
pp. 1017-1024 ◽  
Author(s):  
P. BARRERA ◽  
A. M. TH. BOERBOOMS ◽  
P. N. M. DEMACKER ◽  
L. B. A. VAN DE PUTTE ◽  
H. GALLATI ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Single Dose ◽  
Soluble Receptors ◽  
Dose Methotrexate

AB0159 Tnf membrane-bound and soluble receptors in health and in rheumatoid arthritis

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A834.1-A834
Author(s):  
A. A. Alshevskaya ◽  
J. A. Lopatnikova ◽  
F. F. Vasiliev ◽  
S. V. Sennikov ◽  
N. Shkaruba ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Soluble Receptors ◽  
Membrane Bound

scholarly journals Solution of a mathematical model for the treatment of rheumatoid arthritis

2019 ◽  
Vol 10 (2) ◽  
pp. 12-24 ◽  
Author(s):  
L. Matteucci ◽  
M. C. Nucci
Keyword(s):  
Rheumatoid Arthritis ◽  
Mathematical Model ◽  
Tumor Necrosis ◽  
Unknown Etiology ◽  
Synovial Cells ◽  
Synovial Joint ◽  
Soluble Receptors ◽  
Surface Receptors ◽  
Necrosis Factor ◽  
Pro Inflammatory Cytokines

Abstract Rheumatoid arthritis is an autoimmune disease of unknown etiology that manifests as a persistent inflammatory synovitis and eventually destroys the joints. The immune system recognizes synovial cells as not self and consequently causes lymphocyte and antibody proliferation that is promoted by the pro-inflammatory cytokines, the most significant being tumor necrosis factor TNF-α. In the treatment of rheumatoid arthritis either monoclonal antibodies or soluble receptors are used to neutralize the TNF-α bioactivity, such as sTNFR2, Etanercept and Infliximab. In [M. Jit et al. Rheumatology 2005;44:323-331] a mathematical model that represents the TNF-α dynamics in the inflamed synovial joint within which locally produced TNF-α can bind to cell-surface receptors was proposed. It consists of four coupled ordinary differential equations, that were integrated numerically assuming a range of estimates of the key parameters. In this paper we complement the previous work by determining the general solution of those equations for specific conditions on the parameters. Then we characterize the behavior of TNF-α in the presence of different inhibitors and also evaluate the inhibitors effectiveness in the treatment of rheumatoid arthritis.

Sign in / Sign up

Export Citation Format

Share Document